1-aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats. 2015

Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
Behavioral Neuroscience and Drug Development, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343, Kraków, Poland, nfpopik@cyf-kr.edu.pl.

BACKGROUND In addition to the negative and positive symptoms of schizophrenia, cognitive deficits, including prefrontal cortical dysfunction, are now recognized as core features of this disorder. Compounds increasing the NMDA receptor function via the strychnine-insensitive glycine receptors have been proposed as potential antipsychotics. Depending on the ambient concentrations of glutamate and glycine, 1-aminocyclopropanecarboxylic acid (ACPC) behaves as either a partial agonist or a functional antagonist at the strychnine-insensitive glycine receptors. OBJECTIVE We investigated the procognitive and antipsychotic-like effects of ACPC in rats treated with phencyclidine (PCP) or ketamine (KET), compounds that produce psychotic-like symptoms in humans and laboratory animals. METHODS Cognitive effects were investigated in the novel object recognition (NOR) and attentional set-shifting tests (ASST). In addition, the effects of ACPC were investigated in PCP-induced hyperactivity, conditioned avoidance response (CAR), and prepulse inhibition (PPI) tests. The effects on attention and impulsivity were measured in the five-choice serial reaction time task (5-CSRTT). RESULTS ACPC (200-400 mg/kg) inhibited memory fading in naive rats and like clozapine prevented PCP- and KET-induced amnesia in the NOR. In naive animals, ACPC at 400 but not 200 mg/kg enhanced cognitive flexibility in the ASST, as the animals required fewer trials to reach the criteria during the extra-dimensional phase. In contrast, ACPC did not affect PCP-induced hyperactivity, CAR, and PPI as well as attention and impulsivity in the 5-CSRTT. CONCLUSIONS The present study demonstrates that ACPC enhanced both object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but did not affect impulsivity nor exhibit an antipsychotic-like profile.

UI MeSH Term Description Entries
D007649 Ketamine A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors. 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone,CI-581,Calipsol,Calypsol,Kalipsol,Ketalar,Ketamine Hydrochloride,Ketanest,Ketaset,CI 581,CI581
D008297 Male Males
D008568 Memory Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory.
D010622 Phencyclidine A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust. 1-(1-Phenylcyclohexyl)piperidine,Angel Dust,CL-395,GP-121,Phencyclidine Hydrobromide,Phencyclidine Hydrochloride,Sernyl,Serylan,CL 395,CL395,Dust, Angel,GP 121,GP121
D011930 Reaction Time The time from the onset of a stimulus until a response is observed. Response Latency,Response Speed,Response Time,Latency, Response,Reaction Times,Response Latencies,Response Times,Speed, Response,Speeds, Response
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D000598 Amino Acids, Cyclic A class of amino acids characterized by a closed ring structure. Cyclic Amino Acids,Acids, Cyclic Amino
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001288 Attention Focusing on certain aspects of current experience to the exclusion of others. It is the act of heeding or taking notice or concentrating. Focus of Attention,Selective Attention,Social Attention,Attention Focus,Attention, Selective,Attention, Social,Selective Attentions

Related Publications

Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
January 1996, Polish journal of pharmacology,
Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
November 1999, Pharmacology, biochemistry, and behavior,
Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
August 1995, Neurological research,
Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
February 2020, The international journal of neuropsychopharmacology,
Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
September 2004, Neurotoxicology,
Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
September 2014, The Journal of pharmacology and experimental therapeutics,
Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
December 1996, European journal of pharmacology,
Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
August 1997, Neuropeptides,
Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
March 1976, Biochemical pharmacology,
Piotr Popik, and Malgorzata Holuj, and Agnieszka Nikiforuk, and Tomasz Kos, and Ramon Trullas, and Phil Skolnick
September 2008, The international journal of neuropsychopharmacology,
Copied contents to your clipboard!